anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND AND PURPOSE: Insulin therapies for Type 1 diabetes (T1D) have limitations, such as glucose fluctuations, hypoglycaemia, and weight gain. Only pramlintide is approved with insulin. However, its short half-life limits efficacy, requiring multiple daily injections and increasing hypoglycaemia risk. New strategies are needed to improve glycaemic control. Dual amylin and calcitonin receptor agonists are potent insulin sensitizers developed for Type 2 diabetes (T2D) as they improve glucose control, reduce body weight, and attenuate hyperglucagonemia. However, it is uncertain if they could be used to treat T1D.
EXPERIMENTAL APPROACH: Sprague Dawley rats received a single intravenous injection of streptozotocin (STZ) (50 mg·kg-1) to induce T1D. Humulin (1 U/200 g·day-1 or 2 U/200 g·day-1) was continuously infused, while half of the rats received additional KBP-336 (4.5 nmol·kg-1 Q3D) treatment. Bodyweight, food intake, and blood glucose were monitored throughout the study. An oral glucose tolerance test was performed during the study.
KEY RESULTS: Treatment with Humulin or Humulin + KBP-336 improved the health of STZ rats. Humulin increased body weight in STZ rats, but KBP-336 attenuated these increases and maintained a significant weight loss. The combination exhibited greater blood glucose reductions than Humulin-treated rats alone, reflected by improved HbA1c levels and glucose control. The combination prevented hyperglucagonemia, reduced amylin levels, and increased pancreatic insulin content, indicating improved insulin sensitivity and beta-cell preservation.
CONCLUSION AND IMPLICATIONS: The insulin sensitizer KBP-336 lowered glucagon secretion while attenuating insulin-induced weight gain. Additionally, KBP-336 may prevent hypoglycaemia and improve insulin resistance, which could be a significant advantage for individuals with T1D seeking therapeutic benefits.
Cardiac surgery with cardiopulmonary bypass is associated with serious morbidity and mortality especially in moderate and high-risk patients. This procedure is associated with systemic inflammatory response as a consequence of cardiopulmonary bypass, surgical insult and genetic background of patients leading to organ injury and worse outcome. This pitfall may be worsened by hemodynamic changes with inadequate hemodynamic management.

During and after CPB, substantial changes in macrocirculation and microcirculation are observed and sustain impairment may result in reduced oxygen delivery and/or impaired oxygen extraction. The main consequence is cellular dysorexia that may trigger postoperative organ dysfunction. Rapid identification of cellular dysorexia and rapid hemodynamic management are therefore among key strategies that may reduce mortality.

In this purpose various marker can be considered. Traditionally lactatemia is considered as surrogate of anaerobic metabolism resulting from ischemia. However it interpretation may be challenging particularly in case of reduced hepatic clearance, use of epinephrine or massive blood transfusion. Venous or central venous oxygenation (S(c)VO2), a surrogate of oxygen extraction that is believed to reflect balance between oxygen delivery and consumption, is considered as an acceptable alternative as it was shown to be associated with organ dysfunction in various clinical setting. Nevertheless ScVO2 suffers from the difficulties to define adequate threshold as very high S(c)VO2 as well as low S(c)VO2 may be associated with poor outcome. Recently PCO2 derived dysorexia and perfusion markers have been shown to be predicting outcome in both septic patient and high risk surgical patient. Central venous to arterial difference in PCO2 (ΔPCO2) a global perfusion index is show to be correlated to microcirculation dysfunction and may reflect impaired tissue perfusion. In high risk non-cardiac surgical patients and in septic patient, ΔPCO2 predicted worse outcome better than S(c)VO2 and lactate. Besides this performance may be improve when using a clinically available surrogate based on ΔPCO2. When anaerobic metabolism occurred as a result of sustained hypoxia, CO2 production increases therefore the respiratory quotient (CO2 production (VCO2) and oxygen consumption (VO2) ratio) increases. VCO2/VO2 can be simplified as ΔPCO2 /Ca-vO2 ratio, where Ca-vO2 is arteriovenous O2 content difference. All these variables have never been compared in cardiac surgery setting and their association with microcirculation impaired is poorly documented. The hypotheses is that ΔPCO2, and ΔPCO2 /Ca-vO2 ratio may better predict major postoperative adverse events than blood lactate and S(c)VO2 after cardiac surgery with CPB.
BACKGROUND: Dropped head syndrome (DHS) is followed by severe cervical extension muscle weakness that results in chin-on chest deformity. However, maintaining a neutral cervical position can be temporarily possible, and the diagnosis of DHS might sometimes be difficult. The purpose of the present study is to examine a novel clinical test (DHS test) as the diagnostic utility for objective evaluation that focuses on cervical extension condition in the prone position.
METHODS: One hundred subjects were diagnosed with isolated neck extensor myopathy (INEM)-DHS at our hospital (17 men and 83 women, mean age 75.0 ± 8.5 years), and 62 subjects were enrolled as age-matched controls. The DHS test consisted of three examinations; the first was "Ceiling gazing test" in standing position, the second was horizontal gazing in "Sphinx prone position test", and the third was horizontal gazing in "Hands and knees prone position test". We investigated the sensitivity and specificity of the DHS test for DHS.
RESULTS: The patients showing positive in the INEM-DHS group were 63/100 in Ceiling gaze test, 73/100 in the Sphinx prone position test, and 91/100 in the Hands and knees prone position test. In the control group, 0/62 patients presented positive in the Ceiling gaze test, 4/62 in the Sphinx prone position test, and 0/62 in the Hands and knees prone position test. Sensitivity and specificity of the DHS test were 63.0%/100%, 73.0%/93.5%, and 91.0%/100% in the Ceiling gaze test, Sphinx position prone position test, and Hands and knees prone position test, respectively.
CONCLUSION: The prone position cervical extension test (DHS test) would be useful as a novel objective diagnostic tool for INEM-DHS.
To stabilize vitamin B1s in a preparation, and to improve disintegrability of a solid preparation containing a glucosaminoglycan, such as chondroitin sulfate.SOLUTION: Vitamin B1s are stabilized by containing amino sugars (such as glucosamine) into a preparation containing vitamin B1s. An amount of the amino sugars to be used is an effective amount for stabilizing vitamin B1s, for example, 0.1 pt.wt. or more based on 1 pt.wt. of vitamin B1s. Blending of the amino sugars can improve disintegrability of a solid preparation containing glycosaminoglycans (hyaluronic acid, chondroitin or their salts). An amount of amino sugars to be used is 0.1 pt.wt. or more based on 1 pt.wt. of glycosaminoglycans. The solid preparation, even when pH fluctuates, can suppress formation of a mass of gel of a glycosaminoglycan to improve disintegrability.SELECTED DRAWING: None
This is an Open Label Observational Study with the primary objective to assess brain activity in patients prior to, during and after Ketamine treatment and to assess genetic markers prior to Ketamine treatment. This is a non-interventional study that will observe the Electroencephalogram (EEG) pattern of participants who, per standard of care, are treated with intramuscular Ketamine. The administration of the Ketamine during this study is not considered investigational. The experimental intervention, measurements via EEG, will be offered to patients of the study site presenting for intramuscular (IM) ketamine treatment per the site's established and evidence-based protocol as part of their regular clinical care. Participants in this study have already been determined to have a medically appropriate indication for IM Ketamine treatment, independent of enrollment in this study. Given the requirement, per study protocol, to wear an EEG headset and complete study measures, participants will be compensated by having treatment costs paid by the study sponsor. There will be 36 participants enrolled at one study site.
Accept prednisolone and acupuncture therapy within 10days after onset of Bwll's palsy. Prednisolone used as same as the Arm of Prednisolone. The acupuncture points used as same as the Arm of Acute stage acupuncture.
A method for training a system for predicting a probability of occurrence of cardiac event is provided. The method includes obtaining sets of electrocardiograms of subjects, each set of electrocardiograms comprising at least one electrocardiogram each obtained, a) prior to and b) during or after an occurrence of a cardiac event, or both. The method includes extracting a first approximation of a time series data. The method also includes obtaining electrocardiograph signals that produced the electrocardiograms. The method also includes creating a training dataset from the extracted time series signals and the electrocardiograph signals for training a first and a second approximation of an electrocardiogram for representing an electrocardiograph signal that produced the electrocardiogram. The method further includes training a second model for extracting a cardiac marker from the second approximation of the electrocardiogram of the subject and calculating a probability of occurrence of a cardiac event.
Although the method of buffing using a file or the like exists as a method for managing nails, there are problems relating to the healthy maintenance of the nails and skin, such as worsening damage to the nail surface from there being much abrasion at the same spot, and damage to the skin because management of the nail end and the growth edge is difficult. At the elbow and heel, the stratum corneum is ground and ablated with a pumice stone, a file, or the like, but there are the complications of damage to the skin through excess scraping and the fact that such tools cannot be used except in specific places such as a bath or sink. The disclosed skin cosmetic kneaded composition, wherein an abrasive and keratin hydrolysate are combined with a viscous base material and kneaded, is used. The skin cosmetic kneaded composition is produced by means of introducing the viscous base material, the abrasive, and the keratin hydrolysate into a stirring device, and then stirring. The produced skin cosmetic kneaded composition is used by being applied to the surface of a bodily part that is the nails, the heels, or the elbows, and then the applied material is rubbed at the place of application using the fingertip, palm of the hand, or an implement. A more favorable result can be obtained if an acidic fluid having a pH of 2-4 is used concomitantly at the place of application.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to the sustained- -release of therapeutic compounds from delivery system of medicinal agents. Compound is incapsulated into the delivery system of medicinal agent showing sustained rate of release. Indicated system is administrated as a single dose by epidural route. Delivery system of medicinal agent involves multiple-vesicular liposomes prepared from the group consisting of chicken egg phosphatidylcholines, dipalmitoylphosphatidylcholines, distearoylphosphatidylcholines, dioleoylphosphatidylcholines, dipalmitoylphosphatidylglycerols, dioleoylphosphatidylglycerols and their acceptable combinations. For attenuation of breathing suppression the incapsulated analgetic agent is administrated by epidural route in multiple-vesicular liposome delivery system. EFFECT: enhanced effectiveness of treatment. 24 cl, 1 tbl, 6 dwg, 3 ex
Participants will have access to 60 minutes of voice over PowerPoint slides, available over 5 weeks on an online learning management system, specifically to match exposure and content with the expert modeling video group. The script for PowerPoint will contain content related to the aforementioned seven concepts. There will be static photos, but no expert modeling videos, on PowerPoint slides. The investigator will narrate the voice over PowerPoint.
PURPOSE:To provide the titled cosmetic such as make-up cosmetic, baby powder, body powder, etc., compounded with a specific organic powder such as nylon-6 powder and giving excellent pressed state, feeling to the skin and finished state without using a forming agent. CONSTITUTION:The objective pressed powdery cosmetic is produced by compounding a specific organic powder such as spherical organic powder (e.g. nylon-6 powder, nylon-12 powder, etc.) and fibrous organic powder (e.g. crystalline cellulose) at an amount of 5-50wt% and pressing the mixture without using a forming agent such as a liquid binder. EFFECT:Excellent impact resistance as well as safety. USE:A make-up cosmetic such as face powder, eye color, check color, etc.
The stress management + buddy program (SM-B) includes the same psycho-educative topics and exercises, cognitive and behavioural technique activities as the SM condition. The SM-B in addition to SM utilises one-to-one support through a buddy selected by a participant. A buddy, 18 year or older is a student or a volunteer who is recruited and trained by Indigo Rijnmond. The buddy pairs up with a participant and provides the following: supports participant in managing and filling in tax/welfare papers; 2) helps a participant to get a grip over his/her personal finances; and 3) helps a participant to overcome daily barriers (eg. arranging childcare). Over the duration of the course, the buddy meets up 6 times with a participant every second week in a public area.
To investigate the regulatory effects of Chito-oligosaccharide (COS) on the anti-oxidative, anti-inflammatory, and MAPK signaling pathways. A total of 40 28-day-old weaned piglets were randomly allotted to 4 equal groups [including the control group, lipopolysaccharide (LPS) group, COS group, and COS*LPS group]. On the morning of d 14 and 21, piglets were injected with saline or LPS. At 2 h post-injection, whole blood samples were collected on d 14 and 21, and small intestine and liver samples were collected and analyzed on d 21. The results showed that COS inhibited the LPS-induced increase of malondialdehyde (MDA) concentration and hepatic TNF-α cytokines. COS significantly increased the serum total antioxidant capability (T-AOC) value on d 14, and total superoxide dismutase (T-SOD) and glutathione peroxidase (GSH-PX) activities in both serum and liver on d 21. Furthermore, it increased hepatic catalase (CAT) activity. COS also increased the LPS-induced decrease in serum IgG concentrations. Immunohistochemical analysis results showed that COS significantly increased the jejunal and ileal Caspase 3, and ileal CD4+ values challenged by LPS. Dietary COS decreased the LPS-induced jejunal and ileal BAX and CCL2 mRNA levels, markedly decreased ileal COX2 and SOD1 mRNA levels, while increasing ileal iNOS. Furthermore, COS significantly increased the LPS-induced jejunal and ileal p-P38 and MyD88, as well as jejunal P38, while it effectively suppressed jejunal JNK1, and jejunal and ileal JNK2, p-JNK1, and p-JNK2 protein expressions. These results demonstrated that COS could be beneficial by attenuating LPS-challenged intestinal inflammation via regulating mitochondrial apoptotic and MAPK signaling pathways.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, to the field of ophthalmology. Eye film contains polyvinyl alcohol, arabinogalactan, levofloxacin at a certain ratio of components. Invention expands spectrum of therapeutic action of film by giving it immonomodulatory and membrane-acting properties. ^ EFFECT: invention provides for prolonged action of eye film. ^ 2 dwg, 1 tbl
BACKGROUND: Hepatocellular carcinoma (HCC) poses a significant health burden globally, with high mortality rates despite various treatment options. Immunotherapy, particularly immune-checkpoint inhibitors (ICIs), has shown promise, but resistance and metastasis remain major challenges. Understanding the intricacies of the tumor microenvironment (TME) is imperative for optimizing HCC management strategies and enhancing patient prognosis.
METHODS: This study employed a comprehensive approach integrating multi-omics approaches, including single-cell RNA sequencing (scRNA-seq), bulk RNA sequencing (Bulk RNA-seq), and validation in clinical samples using spatial transcriptomics (ST) and multiplex immunohistochemistry (mIHC). The analysis aimed to identify key factors influencing the immunosuppressive microenvironment associated with HCC metastasis and immunotherapy resistance.
RESULTS: HMGB2 is significantly upregulated in HCCTrans, a transitional subgroup associated with aggressive metastasis. Furthermore, HMGB2 expression positively correlates with an immunosuppressive microenvironment, particularly evident in exhausted T cells. Notably, HMGB2 expression correlated positively with immunosuppressive markers and poor prognosis in HCC patients across multiple cohorts. ST combined with mIHC validated the spatial expression patterns of HMGB2 within the TME, providing additional evidence of its role in HCC progression and immune evasion.
CONCLUSION: HMGB2 emerges as a critical player of HCC progression, metastasis, and immunosuppression. Its elevated expression correlates with aggressive tumor behavior and poor patient outcomes, suggesting its potential as both a therapeutic target and a prognostic indicator in HCC management.
The present invention relates to a purified, easily produced poly-β-1→4-N-acetylglucosamine (p-GlcNAc) polysaccharide species. The p-G1cNAc of the invention is a polymer of high molecular weight whose constituent monosaccharide sugars are attached in a β-1→4 conformation, and which is free of proteins, and substantially free of single amino acids, and other organic and inorganic contaminants. In addition, derivatives and reformulations of p-G1cNAc are described. The present invention further relates to methods for the purification of the p-G1cNAc of the invention from microalgae, preferably diatom, starting sources. Still further, the invention relates to methods for the derivatization and reformulation of the p-G1cNAc. Additionally, the present invention relates to the uses of pure p-G1cNAc, its derivatives, and/or its reformulations.
The present invention provides improved cell delivery compositions. In particular, the invention provides biocompatible endosomolytic agents. In a preferred embodiment, the endosomolytic agents are also biodegradable and can be broken down within cells into components that the cells can either reuse or dispose of. Preferred endosomolytic agents include cationic polymers, particularly those comprised of biomolecules, such as histidine, polyhistidine, polylysine or any combination thereof. Other exemplary endosomolytic agents include, but are not limited to, other imidazole containing compounds such as vinylimidazole and histamine. More particularly preferred are those agents having multiple proton acceptor sites and acting as a 'proton sponge', disrupting the endosome by osmolytic action. In preferred embodiments, the endosomolytic agent comprises a plurality of proton acceptor sites having pKas within the range of 4 to 7, which endosomal lysing component is polycationic at pH 4. The present invention also contemplates the use of these endosomolytic agents as delivery agents by complexation with the desired compound to be delivered. Thus, the present invention also acts as a cell delivery system comprising an endosomolytic agent, a delivery agent, and a compound to be delivered.
Hypotension is the most common adverse reaction seen with intravenous amiodarone. In clinical trials, treatment-emergent, drug-related hypotension was reported as an adverse effect in 288 (16%) of 1836 patients treated with intravenous amiodarone. Clinically significant hypotension during infusions was seen most often in the first several hours of treatment and was not dose related, but appeared to be related to the rate of infusion. Hypotension necessitating alterations in intravenous amiodarone therapy was reported in 3% of patients, with permanent discontinuation required in less than 2% of patients.

Treat hypotension initially by slowing the infusion; additional standard therapy may be needed, including the following: vasopressor drugs, positive inotropic agents, and volume expansion. Monitor the initial rate of infusion closely and do not exceed the recommended rate [see Dosage and Administration ( 2)] . 

In some cases, hypotension may be refractory and result in a fatal outcome [see Adverse Reactions ( 6.2)] .
The participant will arrive fasted at he research center. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 400 mg curcumin. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
Patients receive nab-paclitaxel 80 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle in combination with intermittent relacorilant (150 mg relacorilant once daily on the day before, the day of, and the day after nab-paclitaxel), administered orally under fed conditions. Relacorilant will not be administered on Cycle 1 Day -1.
Desflurane, USP, Liquid for Inhalation is indicated for maintenance of anesthesia in infants and children after induction of anesthesia with agents other thanDesflurane, USP, Liquid for Inhalation, and tracheal intubation.

Desflurane, USP, Liquid for Inhalation, with or without N 2O, and halothane, with or without N 2O were studied in three clinical trials of pediatric patients aged 2 weeks to 12 years (median 2 years) and ASA physical status I or II. The concentration of Desflurane, USP, Liquid for Inhalation required for maintenance of general anesthesia is age-dependent  [See Clinical Studies (14.5)] . 

Changes in blood pressure during maintenance of and recovery from anesthesia with Desflurane, USP, Liquid for Inhalation/N 2O/O 2 are similar to those observed with halothane/N 2O/O 2. Heart rate during maintenance of anesthesia is approximately 10 beats per minute faster with desflurane than with halothane. Patients were judged fit for discharge from post-anesthesia care units within one hour with both Desflurane, USP, Liquid for Inhalation and halothane. There were no differences in the incidence of nausea and vomiting between patients receiving Desflurane, USP, Liquid for Inhalation or halothane.
Test product, dose, mode of administration, batch No.: The lowest dose level will be evaluated as a single dose of 25 U/kg. The three upper dose levels will be evaluated as repeated doses. Patients in each cohort will receive one dose of enzyme every other week for a period of eight weeks, a total of five doses. Dosing will be performed as follows: Cohort 1: 25 U/kg as a single dose - hereafter 50 U/kg; Cohort 2: 100 U/kg; Cohort 3: 200 U/kg. Patients receiving the lowest dose as a single dose will receive the next dose level as a repeated dose. After twenty six weeks the subjects will continue treatment every other week until safety data is available. Safety (AE/SAE) will be monitored at every visit during this period. The dose will be adjusted monthly to account for changes in body weight. The infusion length will be dependent on the dose. Doses of 25 U/kg, 50 U/kg and 100 U/kg will be diluted in 50 ml isotonic sodium chloride and infused over 30 minutes. Infusion of 200 U/kg will be administered in the same manner except for an infusion time of 60 minutes.

Duration of treatment: Half a year (26 weeks)